Tharimmune Rebrands to Canton Strategic Holdings, Pioneering Digital Asset Treasury on Canton Network

Biotech Firm Shifts Focus to Blockchain Integration, Becoming First Public Company with Privacy-Enabled Treasury Strategy

February 19, 2026

Companies mentioned:

Canton Strategic Holdings

Share

Quick Take

• Tharimmune, now Canton Strategic Holdings (NASDAQ: CNTN), aligns with the Canton Network to digitize financial assets, blending biotech roots with blockchain for institutional adoption.
  

• As a Super Validator, it handles $9T monthly transactions on a privacy-focused Layer 1 blockchain, enabling secure, scalable TradFi tokenization.
  

• This pivot could boost valuation in the growing RWA sector, though regulatory and volatility risks persist; watch for expanded biotech-digital synergies.
  

Tharimmune, Inc., a clinical-stage biotechnology company listed on NASDAQ, has officially rebranded to Canton Strategic Holdings, Inc., in a move that underscores its commitment to integrating digital asset strategies with traditional finance. The rebrand, effective February 18, 2026, includes a new ticker symbol, CNTN, and positions the company as a pioneer in leveraging blockchain technology for institutional adoption.

The announcement highlights Canton Strategic Holdings' role as the first and only publicly traded company to implement a digital asset treasury strategy on the Canton Network, a privacy-enabled blockchain platform designed for financial markets. This strategy aims to support the digitization of financial infrastructure, enabling secure and efficient transactions while maintaining privacy and regulatory compliance.

Key Details of the Rebrand

• Name and Ticker Change: The company's common stock began trading under the new ticker CNTN on NASDAQ starting February 18, 2026, prior to market open. The previous ticker was THAR.

Strategic Focus: Canton Strategic Holdings is executing a diversified digital asset treasury strategy on the Canton Network, which processes approximately $9 trillion in monthly transaction volume. The company has been approved as a Super Validator on the network, a role that involves operating core infrastructure to ensure scalability and security.

Biotech Roots Maintained: Despite the pivot toward digital assets, the company remains a clinical-stage biotech firm, blending its expertise in immunology with blockchain innovation.

The rebrand was shared via a post on X (formerly Twitter) by the company's official account, @CantonStrategic, featuring a graphic with the new logo and the tagline "Milestone in Canton Network Digital Asset Treasury Strategy." In the post, the company expressed pride in advancing institutional adoption and thanked partners for their support.

What is the Canton Network?

The Canton Network is a Layer 1 blockchain specifically built for real-world asset (RWA) tokenization and traditional finance (TradFi) institutions. It features configurable privacy controls, allowing financial entities to conduct transactions securely without exposing sensitive data to unauthorized parties. Unlike fully public blockchains where all data is visible, Canton operates as a "network of networks," connecting independent ledgers through a Global Synchronizer for atomic, interoperable transactions.

Key features include:

• Privacy and Controls: Utilizes cryptographic measures and the Daml smart contract language to ensure transaction visibility is limited to involved parties.